Intangible Assets

Dexcom’s CGM brand and clinical credibility support premium pricing and physician preference versus smaller diabetes-device peers, because the product is embedded in diabetes management workflows and backed by FDA-cleared performance claims.

Its regulatory and clinical evidence base is harder to replicate than generic hardware, which raises the bar for entrants relative to traditional glucose-monitoring competitors.

The moat is stronger than most medtech peers that sell interchangeable consumables, but it is still narrower than platform-like healthcare franchises because alternative CGM systems remain available from Abbott and Medtronic.

Intangible strength is durable over 5–10 years because reimbursement, clinician trust, and patient familiarity reinforce adoption, but these advantages are not exclusive enough to imply structural dominance.

Switching Costs

Once patients and clinicians are trained on Dexcom’s app, alerts, data-sharing, and insulin-dosing workflows, switching creates friction that supports retention versus simpler monitoring devices.

Integrated use with diabetes management routines makes replacement costly in time and behavior, which is stronger than in many device categories where products are bought episodically.

Switching costs are meaningful but not absolute because Abbott’s Libre and other CGM options can be adopted without requiring customers to stay on Dexcom’s platform, limiting lock-in versus software-like peers.

The company’s recurring sensor model and ecosystem of connected data tools improve retention more than one-time device sales, but the moat remains below exceptional because interoperability and competing CGM ecosystems preserve choice.

Network Effects

Dexcom benefits from some data-sharing and caregiver connectivity effects, because more users and clinicians familiar with its platform can improve workflow adoption and patient support.

Clinical familiarity can create a soft network effect among endocrinologists and diabetes educators, which helps Dexcom versus less established peers.

The effect is limited because CGM value is primarily individual and clinical rather than a true multi-user network, so one customer’s adoption does not materially increase another customer's utility.

Compared with platform businesses, Dexcom’s network effects are modest and do not create peer dependency or ecosystem control.

Cost Advantage

Dexcom’s scale in sensors, manufacturing, and distribution likely lowers unit costs versus smaller entrants, which supports gross margin resilience relative to niche competitors.

Its installed base can spread R&D and regulatory costs across more revenue than emerging CGM challengers, improving economics versus subscale peers.

The company does not appear to have a decisive cost advantage over Abbott, which is a larger diversified healthcare competitor with substantial scale and manufacturing leverage.

Cost advantage is therefore real but not dominant, because peer scale and ongoing product competition keep pricing power from becoming structurally superior.

Efficient Scale

CGM is a regulated medical-device market where clinical validation, reimbursement access, and manufacturing quality create meaningful barriers that favor a few scaled players.

Dexcom operates in a market that can support only a limited number of large competitors at attractive economics, which strengthens efficient-scale characteristics versus fragmented device categories.

The market is not a pure natural monopoly because Abbott already competes at scale and Medtronic remains present, so Dexcom’s position is advantaged but not exclusive.

Efficient scale is stronger than in most consumer-health categories, but peer competition is still sufficient to prevent structural dominance.

Overall Score

Dexcom has a strong but not dominant moat, led by switching costs, regulatory/clinical intangibles, and efficient-scale barriers that support retention and pricing power versus most peers, while network effects remain modest and Abbott’s large-scale CGM competition prevents exceptional structural control.